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using ABI Info, EconLit, PsychInfo, MEDLINE, 
CANCERLIT, AIDSLINE, HealthStar; databases were
searched from 1990–2001. Articles identiﬁed comprised
productivity measured by subjective (self-report ques-
tionnaires) and objective (computer-based tracking
systems) techniques; subjective instruments included both
generic and disease-speciﬁc measures. Identiﬁed instru-
ments were evaluated on psychometric properties, 
generalizability to different populations, and administra-
tor/respondent burden. RESULTS: Five generic subjective
measures were identiﬁed—the Endicott Work Produc-
tivity Scale; Health and Labor Questionnaire; Health and
Work Questionnaire; Work Limitations Questionnaire;
and the Work Productivity and Activity Impairment
Questionnaire (WPAI)—that could theoretically be used
in any working population. All subjective instruments
showed adequate to good reliability. However, these
instruments were usually validated against other subjec-
tive measures (such as health-related quality of life), as a
uniform measure of “productivity” does not exist. The
WPAI was the most frequently used instrument and has
also been modiﬁed to measure productivity reductions
associated with speciﬁc diseases (e.g., allergic rhinitis,
gastro-esophageal reﬂux disease). Objective assessments
have been carried out to measure employee productivity
for tasks where individual output could be quantiﬁed
(e.g., claims processed, telephone inquiries handled). To
avoid respondent bias, these studies utilized computer-
based tracking systems to determine productivity reduc-
tion attributable to illness. CONCLUSIONS: Subjective
and objective productivity assessments offer different
beneﬁts: while subjective instruments can be used in 
populations with different illnesses and/or jobs, objective
measures minimize respondent bias but are associated
with restricted generalizability and are burdensome to
carry out in practice.
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OBJECTIVE: Allogeneic stem cell transplantations 
(SCT) for leukaemias are known to be one of the most
expensive medical procedures. In the Netherlands, a 
few licensed hospitals perform allogeneic SCT. However,
the budgets they receive are not sufﬁcient (for instance
due to the application of donor lymphocyte infusions).
We calculated the direct medical costs of patients 
who underwent allogeneic SCT to support a budget 
revision. METHODS: Costs of HLA-identical sibling
bone marrow transplantation (BMT), bone marrow
transplantation from a Matched Unrelated Donor (MUD)
and peripheral blood stem cell transplantation (PBSCT)
were identiﬁed. Costs were determined by two comple-
mentary methods. First, medical consumption for these
patients was determined and multiplied by the unit costs
of each of the items. Second, a structural program for
allogeneic transplantations brings along costs that are not
expressed in the registration of the medical consumption
of patients (e.g. HLA-typing and selection of the unre-
lated donor). The costs of these items were identiﬁed in
cooperation with the ﬁnancial departments of the hospi-
tals, and by expert opinion. RESULTS: The average costs
per transplanted patient were €98,334 (BMT), €151,754
(MUD), and €98,977 (PBSCT) for a follow-up period of
2 years. This includes the costs of hospitalizations,
medical procedures, medication, donor identiﬁcation and
the costs of patients who were not transplanted after they
had been planned to receive an allograft. The majority of
costs were made prior to and during hospitalization for
graft infusion. In MUD transplantation the costs of
ﬁnding a suitable donor comprise nearly one third of total
costs. CONCLUSION: This cost analysis gives a proper
indication of the costs associated with performing differ-
ent types of allogeneic SCTs and maintaining a structural
transplantation program in the Netherlands. The results
of this analysis will be used in determining a new budget
for allogeneic SCTs in the Netherlands.
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OBJECTIVES: The objective of this health technology
assessment commissioned by the German Agency for
Health Technology Assessment at DIMDI/German
Federal Ministry of Health was to conduct a systematic
review of the cost-effectiveness of new cervical cancer
screening techniques, and to perform a decision-analysis
in the context of the German health care system.
METHODS: A systematic literature review and assess-
ment on quality/transferability of data was performed
using instruments developed by the German Scientiﬁc
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Working Group Technology Assessment for Health Care.
The German Cervical Cancer Model Group, an interna-
tional and interdisciplinary network, was established to
1) assess German clinical practice patterns; 2) create a
database of German epidemiological, clinical, and eco-
nomic model parameters; 3) develop a German decision
model based on previously published and validated 
international models, and 4) perform cost-effectiveness
analyses. RESULTS: Based on international studies, 
the discounted incremental cost-effectiveness ratios
(ICER) compared to conventional smears were
US$10,000–37,000 per life year saved (LYS) for liquid
based testing, 22,000–29,000 US$/LYS for automated
primary screening, and 16,000–48,000 US$/LYS for 
automated re-screening technologies, assuming a 3-year
screening interval, but was much less attractive for more
frequent screening intervals. In comparison, for the
German health care context screening with a combina-
tion of liquid-based preparation plus computer-assisted
smear-analyses compared to conventional smears resulted
in 31,000 €/LYS for a 3-year screening interval, 56,000
€/LYS for a 2 year screening interval, and 300,000 
€/LYS for annual screening. Results were most sensitive
to assumptions about the costs and performance of
screening tests and population compliance. CONCLU-
SIONS: Technologies improving performance of cervical
cancer screening are reasonably cost-effective at screen-
ing intervals of three years and greater. Based on the
current clinical standard of annual cervical cancer screen-
ing in Germany, the introduction of new screening 
technologies would likely not be cost-effective without 
a reduction in screening frequency.
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ONCE-PER-CYCLE FIXED-DOSE
ADMINISTRATION OF PEGFILGRASTIM
REDUCED RESOURCE UTILIZATION AND
COSTS COMPARED WITH DAILY FILGRASTIM
IN THE PREVENTION OF CHEMOTHERAPY-
INDUCED NEUTROPENIA
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OBJECTIVES: A single 6mg once-per-cycle injection of
pegﬁlgrastim was compared with daily ﬁlgrastim (mean
10.5 days/cycle) in a double-blind, randomized, multina-
tional, phase 3 study in patients (pts) receiving 4 cycles
of myelosuppressive chemotherapy. The observed inci-
dences of febrile neutropenia (13% v 20%), hospitaliza-
tion (18% v 31%), and IV anti-infective use (17% v 21%)
were lower across all cycles in the pegﬁlgrastim arm. 
Pegﬁlgrastim was safe and well tolerated. This economic
analysis was conducted to determine if pegﬁlgrastim
would lead to a reduction in resource utilization and cost.
METHODS: Duration of all-cause hospitalization, IV
anti-infective use, and transfusion in each cycle and across
all cycles were compared. Unit costs were available for
ﬁve participating countries: Germany, Italy, the Nether-
lands, Spain, and the US. Each set of country speciﬁc unit
costs was applied to the entire study sample, and the total
cost was calculated as the sum of costs of hospitalization,
IV anti-infectives, and transfusion. All costs were con-
verted into year 2000 Euros. RESULTS: Economic analy-
sis was performed on 152 pts (77 in pegﬁlgrastim arm)
evaluable for efﬁcacy (97% of all randomized pts). The
mean [sd] durations of all cause hospitalizations (1.18
[3.10] v 3.77 [8.72] days) and IV anti-infective use (0.70
[2.34] v 2.32 [6.09] days) were signiﬁcantly lower 
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